Skip to main content
SpringerLink
Log in

Biology of the Striatum

  • Chapter
Biology of Brain Dysfunction

Abstract

In the last 20 years, there has been a significant advance in our understanding of the pathophysiology and biochemistry of disorders of the basal ganglia. The first steps were taken with the demonstration of the role of copper and ceruloplasmin in hepatolenticular degeneration, or Wilson’s disease. A few years later, it was found that dopamine is highly concentrated in the basal ganglia of the brain and that it is deficient in Parkinson’s disease. This led to the use of the precursor L-dopa in the therapy of Parkinson’s disease, a development which proved to be important both for the patients and for the attention paid by neurobiologists to this part of the brain.

The studies from the author’s laboratory quoted in this chapter were supported in part by grants from the Medical Research Council of Canada, the Committee to Combat Huntington’s Disease (Los Angeles Chapter), the United Parkinson Foundation, and the W. Garfield Weston Foundation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. A. Barbeau and F. H. McDowell, “L-DOPA and Parkinsonism,” pp. 1–433, F. A. Davis, Philadelphia (1970).

    Google Scholar 

  2. A. Barbeau, l-DOPA therapy in Parkinson’s disease: A critical review of nine years’ experience, Can. Med. Ass. J 101:781–800(1969).

    Google Scholar 

  3. N. E. Andén, A. Dahlström, K. Fuxe, and K. Larsson, Mapping out of catecholamine and 5-hydroxytryptamine neurons innervating the telencephalon and the diencephalon, Life Sci 4:1275–1280 (1965).

    Article  Google Scholar 

  4. A. Barbeau, Functions of the striatum, in “Monoamines, noyaux gris centraux et syndrome de Parkinson,” (J. de Ajuriaguerra and G. Gauthier, eds.) pp. 385–402, Masson et Cie, Paris (1971).

    Google Scholar 

  5. A. Barbeau, Role of dopamine in the nervous system, in “Monographs in Human Genetics” (J. François, ed.) Vol. 6, pp. 114–136, Karger, Basel (1972).

    Google Scholar 

  6. A. Barbeau, Contributions of levodopa therapy to the neuropharmacology of akinesia, in “Parkinson’s Disease (Rigidity, Akinesia, Behavior)” (J. Siegfried, ed.) Vol. 1, pp. 152–174 Hans Huber, Publ., Berne (1972).

    Google Scholar 

  7. A. Barbeau, Dopamine and mental function, in “l-DOPA and Behavior” (S. Malitz, ed.) pp. 9–33, Raven Press, New York (1972).

    Google Scholar 

  8. N. A. Buchwald, C. D. Hull, L. M. Vernon, and G. A. Bernardi, Physiological and psychological aspects of basal ganglia functions, in “Psychotropic Drugs and Dysfunctions of the Basal Ganglia,” pp. 82–92, P.H.S. Publication No. 1938, Government Printing Office, Washington, D.C. (1969).

    Google Scholar 

  9. D. Albe-Fessard, G. Guiot, Y. Lamarre, and G. Arfel, Activation of thalamocortical projections related to tremorogenic processes, in “The Thalamus” (D. Purpura and M. D. Yahr, eds.) pp. 237–253, Columbia University Press, New York (1966).

    Google Scholar 

  10. W. R. Hess, “Vegetative Funktionen und Zwischenhirn,” Schwabe, Basel (1946).

    Google Scholar 

  11. D. Denny-Brown, Diseases of the basal ganglia. Their relation to disorders of movements, Lancet 2:1099 (1960).

    Article  Google Scholar 

  12. R. Jung and R. Hassler, The extrapyramidal motor system, in “Handbook of Physiology,” Vol. 2, pp. 863–927, American Physiological Society, Washington, D.C. (1960).

    Google Scholar 

  13. A. Carlsson, The occurrence, distribution and physiological role of catecholamines in the nervous system, Pharmacol. Rev 11:490–493 (1959).

    Google Scholar 

  14. O. Hornykiewicz, Dopamine (3-hydroxytyramine) and brain function, Pharmacol. Rev 18:925–964 (1966).

    Google Scholar 

  15. M. Joubert and A. Barbeau, Akinesia in Parkinson’s disease, in “Progress in Neuro-Genetics” (A. Barbeau and J. R. Brunette, eds.) pp. 366–376, Excerpta Medica Foundation, Amsterdam (1969).

    Google Scholar 

  16. J. de Ajuriaguerra, La notion d’akinésie, in “Monoamines, noyaux gris centraux et syndrome de Parkinson” (J. de Ajuriaguerra and G. Gauthier, eds.) pp. 565–579 Masson et Cie, Paris (1971).

    Google Scholar 

  17. J. Brumlik and B. Boshes, The mechanism of bradykinesia in Parkinsonism, Neurology 16:337–344 (1966).

    Article  Google Scholar 

  18. K. Kleist, “Gehirnpathologie,” J. A. Barth, Leipzig (1934).

    Google Scholar 

  19. R. S. Schwab and I. Zieper, Effects of mood, motivation, stress and alertness on the performance of Parkinson’s disease, Psychiat. Neurol (Basel) 150:345–357 (1965).

    Article  Google Scholar 

  20. A. Barbeau, G. F. Murphy, and T. L. Sourkes, Excretion of dopamine in diseases of basal ganglia, Science 133:1706–1707 (1961).

    Article  Google Scholar 

  21. A. Barbeau, Dopamine and dopamine metabolites in Parkinson’s disease. A review, Proc. Aust. Ass. Neurologists 5:95–100 (1968).

    Google Scholar 

  22. A. Barbeau, La maladie de Parkinson et 1e métabolisme des amines cérébrales, Rev. Praticien 20:5165–5173 (1970).

    Google Scholar 

  23. R. Papeschi, P. Molina-Negro, T. L. Sourkes, J. Hardy, and C. Bertrand, Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson’s disease and other dyskinesias, Neurology 20:991–1001 (1970).

    Article  Google Scholar 

  24. U. K. Rinne and V. Sonninen, Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson’s disease, Neurology 22:62–69 (1972).

    Article  Google Scholar 

  25. W. Birkmayer and O. Hornykiewicz, Der l-dioxyphenylalanin (L-DOPA)-Effekt beim Parkinson Syndrom des Menschen: Zur Pathogenese und Behandlung des Parkinson Akinese, Arch. Psychiat. Nervenkrank 203:560–572 (1962).

    Article  Google Scholar 

  26. H. Corrodi, K. Fuxe, and U. Ungerstedt, Evidence for a new type of dopamine receptor stimulating agent, J. Pharm. Pharmacol 23:989–991 (1971).

    Article  Google Scholar 

  27. A. M. Ernst, Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats, Psychopharmacologia 10:316–323 (1967).

    Article  Google Scholar 

  28. R. S. Schwab, L. V. Amador, and J. Y. Lettvin, Apomorphine in Parkinson disease, Trans. Am. Neurol. Ass 76:251–253 (1951).

    Google Scholar 

  29. J. Braham, I. Sarova-Pinhas, and Y. Goldhammer, Apromorphine in Parkinsonian tremor. Brit Med. J 3:768 (1970).

    Article  Google Scholar 

  30. P. Castaigne, D. LaPlanne, and G. Dordain, Clinical experimentation with apomorphine in Parkinson’s disease, Res. Commun. Chem. Pathol. Pharmacol 2:154–158 (1971).

    Google Scholar 

  31. G. C. Cotzias, P. S. Papavasiliou, C. Fehling, B. Kaufman, and I. Mena, Similarities bebetween neurologic effects of l-DOPA and apomorphine, New Engl. J. Med 232:31–33 (1970).

    Article  Google Scholar 

  32. S. E. Düby, L. K. Dahl, and G. C. Cotzias, Coupling of hypotensive and anti-Parkinson effects with two dopaminergic drugs, Trans. Ass. Am. Physicians 84:289–296 (1971).

    Google Scholar 

  33. U. Ungerstedt, L. L. Butcher, S. G. Butcher, N. E. Anden, and K. Fuxe, Direct chemical Stimulation of dopaminergic mechanisms in the neostriatum of the rat, Brain Res 14:461–470 (1969).

    Article  Google Scholar 

  34. K. M. Taylor and S. H. Snyder, Amphetamine: Differentiation by D and L isomers of behavior involving brain norepinephrine or dopamine, Science 168:1487–1488 (1970).

    Article  Google Scholar 

  35. S. H. Snyder, K. M. Taylor, J. T. Coyle, and J. L. Meyerhoff, The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs, Am. J. Psychol 127:199–207 (1970).

    Google Scholar 

  36. A. Barbeau, H. Mars, and L. Gillo-Joffroy, Adverse clinical side-effects of levodopa therapy, in “Recent Advances in Parkinson’s Disease” (F. H. McDowell and C. H. Markham, eds.) Vol. 8, pp. 203–207, Contemporary Neurology, F. A. Davis, Philadelphia (1971).

    Google Scholar 

  37. A. Olivier, A. Parent, H. Simard, and L. J. Poirier, Cholinesterasic striatopallidal and striatonigral efferents in the cat and the monkey, Brain Res 18:273–282 (1970).

    Article  Google Scholar 

  38. N. E. Andén, M. G. M. Jukes, and A. Lundberg, The effect of DOPA on the spinal cord. 2. A pharmacological analysis, Acta Phys. Scand 67:387–397 (1966).

    Article  Google Scholar 

  39. N. E. Andén, A. Rubenson, K. Fuxe, and T. Hökfelt, Evidence for dopamine receptor Stimulation by apomorphine, J. Pharm. Pharmacol 19:637–639 (1967).

    Article  Google Scholar 

  40. A. Barbeau, Dopamine and disease, Can. Med. Ass. J 103:824–832 (1970).

    Google Scholar 

  41. G. Bryson, Biogenic amines in normal and abnormal behavioral states, Clin. Chem 17:5–26 (1971).

    Google Scholar 

  42. B. B. Brodie and W. D. Reid, Serotonin in brain: Functional considerations, Advan. Pharmacol 6:97 (1968).

    Article  Google Scholar 

  43. J. J. Schildkraut, The catecholamine hypothesis of affective disorders: A review of supporting evidence, Am. J. Psychol 122:509–522. (1965).

    Google Scholar 

  44. F. A. Mettler and A. Crandell, Relation between parkinsonism and psychiatric disorder, J. Nerv. Ment. Dis 129:551–563 (1959).

    Article  Google Scholar 

  45. N. S. Kline, and F. A. Mettler, The extrapyramidal system and schizophrenia, in “Extrapyramidal System and Neuroleptics” (J. M. Bordeleau, ed.) pp 487–491, Presses de l’Université de Montréal, Montréal (1961).

    Google Scholar 

  46. E. L. Bliss, and J. Ailion, Relationship of stress and activity to brain dopamine and homovanillic acid, Life Sci 10:1161–1169 (1971).

    Article  Google Scholar 

  47. M. I. Botez and A. Barbeau, Role of subcortical structures and particularly of the thalamus in the mechanisms of speech and language. A review, Intern. J. Neurol 8:300–320 (1971).

    Google Scholar 

  48. J. V. Beardsley and F. Puletti, Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment, Arch. Neurol 25:145–150 (1971).

    Article  Google Scholar 

  49. R. Klaiber, J. Siegfried, W. H. Ziegler, and E. Perret, Psychomotor effects of l-DOPA combined with a decarboxylase inhibitor on parkinsonian patients, Europ. J. Clin. Pharmacol 3:172–175 (1971).

    Article  Google Scholar 

  50. J. Barbizet, Rôle du lobe frontal dans les conduites mnésiques, Presse Méd 79:2033–2037 (1971).

    Google Scholar 

  51. G.C. Marsh, C. H. Markham, and R. Ansel, Levodopa’s awakening effect on patients with parkinsonism, J. Neurol. Neurosurg. Psychiat 34:209–218 (1971).

    Article  Google Scholar 

  52. T. C. Gutherie, H. S. Dunbar, and A. Weider, l-DOPA: Effect on highest integrative functions in parkinsonism, Trans. Am. Neurol. Ass 95:250–252 (1970).

    Google Scholar 

  53. A. W. Loranger, H. Goodell J. E. Lee, and F. H. McDowell, Levodopa treatment of Parkinson’s syndrome. Improved intellectual functioning, Arch. Gen. Psychiat 26:163–168 (1972).

    Article  Google Scholar 

  54. M. Riklan, Levodopa and behavior, Neurology 22:(Part 2):43–55 (1972).

    Article  Google Scholar 

  55. D. C. Garron, H. L. Klawans, and F. Narin, Intellectual functioning of persons with idiopathic parkinsonism, J. Nerv. Ment. Dis 154:445–452 (1972).

    Article  Google Scholar 

  56. A. Barbeau, Long term appraisal of levodopa therapy, Neurology 22:(Part 2):22–24 (1972).

    Article  Google Scholar 

  57. M. I. Botez and A. Barbeau, The neuropsychology of akinesia. 1. Kohs block design test before and after levodopa therapy, in “Parkinson’s Disease (Rigidity, Akinesia, Behavior)” (J. Siegfried, ed.) Vol. 2, Hans Huber Publ., Berne (1972).

    Google Scholar 

  58. E. A. Spiegel and E. G. Szekely, Prolonged sitmulation of the head of the caudate nucleus, Arch. Neurol 4:55–61 (1961).

    Article  Google Scholar 

  59. U. Ungerstedt, 6-Hydroxydopamine-induced degeneration of central monoamine neurons, Europ. J. Pharmacol 5:107–110 (1968).

    Article  Google Scholar 

  60. H. Thoenen, R. A. Mueller, and J. Axelrod, Trans-synaptic induction of tyrosine hydroxylase, J. Pharmacol. Exptl. Therap 169:249–254 (1969).

    Google Scholar 

  61. B. Jacks, J. De Champlain, and J. P. Cordeau, Effect of 6-OH-dopamine on the central nervous system of rats, Proc. Can. Fed. Biol. Soc 13:136 (1970).

    Google Scholar 

  62. A. Pletscher, Regulation of catecholamine turnover by variations of enzyme levels, Pharmacol Rev 24:225–232 (1972).

    Google Scholar 

  63. P. B. Molinoff and J. Axelrod, Biochemistry of catecholamines, Ann. Rev. Biochem 40:465–500 (1971).

    Article  Google Scholar 

  64. K. Yamada, J. L. Minnich, J. Donaldson, and A. Barbeau, Effect of 3,4-dihydroxyphenyl-acetic acid on catecholamines and serotonin in rat striatum, J. Neurol. Sci 18:311–315 (1973).

    Article  Google Scholar 

  65. R. A. Mueller, H. Thoenen, and J. Axelrod, Effect of pituitary and ACTH on the maintenance of basal tyrosine hydroxylase activity in the rat adrenal gland, Endocrinology 86:751–755 (1970).

    Article  Google Scholar 

  66. R. Weinshilbaum and J. Axelrod, Dopamine-β-hydroxylase activity in the rat after hypophysectomy, Endocrinology 87:894–899 (1970).

    Article  Google Scholar 

  67. H. Friesen, H. Guyda, P. Hwang, J. E. Tyson, and A. Barbeau, Functional evaluation of prolactin secretion. A guide to therapy, J. Clin. Invest 51:706–709 (1972).

    Article  Google Scholar 

  68. S. W. Spaulding, G. N. Burrow, R. Donabedian, and M. Van Woert, l-DOPA suppression of thyrotropin releasing hormone response in man, J. Clin. Endocrinol. Metab 35:182–185 (1972).

    Article  Google Scholar 

  69. D. Ganten, J. L. Minnich, P. Granger, K. Hayduk, H. M. Brecht, A. Barbeau, R. Boucher, and J. Genest, Angiotensin-forming enzyme in brain tissue, Science 173:64–65 (1971).

    Article  Google Scholar 

  70. J. L. Minnich, D. Ganten, A. Barbeau, and J. Genest, Subcellular localization of cerebral renin-like activity, in “Hypertension ‘72” (J. Genest and E. Koiw, eds.) pp. 432–435, Springer-Verlag, Berlin (1972).

    Google Scholar 

  71. J. L. Minnich, J. Donaldson, and A. Barbeau, Modification des concentrations cérébrales en monoamines par l’angiotensine, Union Med. Can 102:903–906 (1973).

    Google Scholar 

  72. E. Roberts, An hypothesis suggesting that there is a defect in the GABA system in schizophrenia, Neurosc. Res. Progr. Bull 10:468–482 (1972).

    Google Scholar 

  73. A. Barbeau, Biochemistry of Parkinson’s disease, Excerpta Med. Intern. Congr. Ser 38:152 (1961).

    Google Scholar 

  74. A. Barbeau, Treatment of Parkinson’s disease with levodopa and Ro 4-4602. Review and present status, in “Advances in Neurology,” vol. 2 (M. D. Yahr, ed.), Raven Press, New York, pp. 173–198 (1973).

    Google Scholar 

  75. A. Barbeau, Biochemistry of Huntington’s chorea, in “Huntingtons Chorea: 1872–1972” (A. Barbeau, T. N. Chase, and G. W. Paulson, eds.), Raven Press, New York (1973).

    Google Scholar 

  76. A. Barbeau, The biochemistry of Huntington’s chorea. Recent developments, Psychiat. Forum (1973).

    Google Scholar 

  77. A. J. Kastin and A. Barbeau, Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson’s disease, Can Med. Ass. J 107:1079–1081 (1972).

    Google Scholar 

  78. O. Hornykiewicz, Biochemical and pharmacological aspects of akinesia, in “Parkinson’s Disease (Rigidity, Akinesia, Behavior)” (J. Siegfried, ed.) Vol. 1, pp. 127–149, Hans Huber Publ., Berne (1972).

    Google Scholar 

  79. O. Hornykiewicz, Dopamine: Its physiology, pharmacology and pathological neurochemistry, in “Biogenic Amines and Physiological Membranes” (J. H. Biel and L. G. Abood, eds.) Part 2, pp. 173–258, Dokker, New York (1971).

    Google Scholar 

  80. O. Hornykiewicz, Neurochemistry of parkinsonism, in “Handbook of Neurochemistry” (A. Lajtha, ed.) Vol. 7, pp. 465–501, Plenum Press, New York. (1972).

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurobiology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada

    André Barbeau

Authors
  1. André Barbeau
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. New York State Institute for Basic Research in Mental Retardation, Staten Island, New York, USA

    Gerald E. Gaull

  2. Mount Sinai School of Medicine, City University of New York, New York, New York, USA

    Gerald E. Gaull

Rights and permissions

Reprints and permissions

Copyright information

© 1973 Plenum Press, New York

About this chapter

Cite this chapter

Barbeau, A. (1973). Biology of the Striatum. In: Gaull, G.E. (eds) Biology of Brain Dysfunction. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-2670-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-2670-0_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-2672-4

  • Online ISBN: 978-1-4684-2670-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation